Study of islatravir and ulonivirine for new HIV patients
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HIV-1 (not HIV-2).
- You must have never taken any HIV medications before.
- Your viral load (amount of virus in blood) must be at least 500 copies/mL.
- You cannot have active hepatitis B or C, or an active AIDS-related infection.
- You must not have had most cancers in the last 5 years, except for some skin or anal cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests a new investigational drug called Codivir added to standard HIV treatment for people who have never taken HIV medications before. It aims to see if adding Codivir helps control the virus better and is safe.
This Phase 3 study tests UB-421 added to a customized (optimized) set of existing HIV medicines for people with HIV that is resistant to multiple drugs. It may help reduce the virus more effectively when standard treatments have not been enough.
Hear when a new Human Immunodeficiency Virus Type 1 (HIV-1) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.